Trial of Pamrevlumab (FG-3019), in Non-Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)

Inclusion Criteria:

Written consent/assent by participant and/or legal guardian as per regional and/or institutional review board (IRB) requirements
Non-ambulatory
Brooke Score for Arms and Shoulders ≤5
Diagnosis of DMD by medical history and confirmed Duchenne mutation in available genetic testing using a validated genetic test
Able to perform spirometry
Able to undergo cardiac and extremity (upper arm) MRI
Percent predicted FVC between 40 and 90, inclusive
At least one historical ppFVC predicted value within 18 months of baseline
Left ventricular ejection fraction ≥ 45% as determined by cardiac MRI at screening or within 3 months prior to Day 0
Participants currently receiving heart failure cardiac medications (for example, angiotensin converting enzyme inhibitors, angiotensin-receptor blockers, and beta-blockers) must achieve a stable regimen for at least 3 months prior to screening
On a stable dose of corticosteroids for a minimum of 6 months prior to screening with no substantial change in dosage for a minimum of 3 months (except for adjustments for changes in body weight) prior to screening and no foreseen change in corticosteroid use during the course of study participation
Received pneumococcal vaccine and is receiving annual influenza vaccinations
Adequate renal function: cystatin C ≤1.4 mg/liter (L)

Adequate hematological function

Platelets >100,000/microliter (μL)
Hemoglobin >12 grams (g)/deciliter (dL)
Absolute neutrophil count >1500/μL

Adequate hepatic function

No history or evidence of liver disease
Gamma glutamyl transferase (GGT) ≤3 x upper limit of normal (ULN)
Total bilirubin ≤1.5 x ULN
If sexually active, will use medically accepted contraceptives during participation in the study and for 3 months after the last dose of study drug

Exclusion Criteria:

Requires ≥16 hours continuous ventilation
Prior or ongoing medical condition that, in the investigator's opinion, could adversely affect the safety of the participant, makes it unlikely that the course of 156 weeks of treatment and follow-up would be completed, or could impair the assessment of study results
Anticipated spine surgery within 156 weeks

Severe uncontrolled heart disease, including any of the following:

Need for intravenous diuretics or inotropic support within 3 months prior to screening
Hospitalization for a heart failure exacerbation or arrhythmia in last 3 months
Arrhythmia requiring anti-arrhythmic therapy
Hospitalization due to respiratory failure in the last 6 weeks
Poorly controlled asthma or underlying lung disease such as bronchopulmonary dysplasia
Known or suspected active hepatitis B or C or history of human immunodeficiency virus (HIV)
Body mass index (BMI) ≥40 kilograms (kg)/square meter (m^2) or weight >117 kg
Exposure to another investigational drug or another approved product for DMD (for example, eteplirsen or golodirsen) within 28 days prior to start of study treatment
Exposure to another investigational drug or another approved product for DMD (e.g. eteplirsen) within 28 days prior to start of study treatment (or 5 half-lives of the product whichever is longer) prior to first screening visit with the exception of deflazacort. Use of deflazacort, if regarded by the principal investigator as standard of care, is allowed.

For more information on this trial, visit clinicaltrials.gov.